Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval

Clinical trial NCT04821063 · COMPLETED

Trial details

NCT number: NCT04821063
Sponsor: Italfarmaco
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Duchenne and Becker Muscular Dystrophy Polycytemia Vera

Start date: 2021-04-13
Primary completion: 2021-06-18
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.